Cell-penetrating peptides (CPPs), such as nona-arginine (9R), poorly translocate siRNA into cells. Our studies demonstrate that attaching 9R to ligands that bind cell surface receptors quantitatively increases siRNA uptake and importantly, allows functional delivery of complexed siRNA. The mechanism involved accumulation of ligand-9R:siRNA microparticles on the cell membrane, which induced transient membrane inversion at the site of ligand-9R binding and rapid siRNA translocation into the cytoplasm. siRNA release also occurred late after endocytosis when the ligand was attached to the L isoform of 9R, but not the protease-resistant 9DR, prolonging mRNA knockdown. This critically depended on endosomal proteolytic activity, implying that partial CPP degradation is required for endosome-tocytosol translocation. The data demonstrate that ligand attachment renders simple polycationic CPPs effective for siRNA delivery by restoring their intrinsic property of translocation.
INTRODUCTION
Cell-penetrating peptides (CPPs) can translocate into cells in an autonomous and receptor-independent manner with low cytotoxicity and immunogenicity (reviewed in Fonseca et al., 2009; Gump and Dowdy, 2007) . Many primary cell membranes that constitute an impermeable barrier to reagents that easily transfect cell lines are permeable to CPPs. CPPs are thus promising delivery vehicles for a vast range of biologically functional cargo (Du et al., 2011; Eguchi and Dowdy, 2009; El-Sayed et al., 2009; Fawell et al., 1994; Jones et al., 2005; Looi et al., 2011; Schwarze et al., 1999) . How CPPs enter cells and access the cytoplasm are areas of active investigation (Erazo-Oliveras et al., 2012; Schwarze and Dowdy, 2000) . Depending on CPP composition, concentration, cell type, and the experimental conditions used, energy-independent as well as endocytic pathways are involved in CPP uptake and translocation (Duchardt et al., 2007; Fischer et al., 2004; Fretz et al., 2007; Futaki et al., 2007; Hirose et al., 2012; Madani et al., 2011; Payne et al., 2007; Rothbard et al., 2005; Verdurmen et al., 2011; Wadia et al., 2004) . Cationic arginine-rich CPPs (R-CPPs) can noncovalently complex with small interfering RNA (siRNA). Despite their typical ability to effectively translocate biological macromolecules, R-CPPs are poor vehicles for cytoplasmic delivery of siRNA. For measurable mRNA knockdown, a huge excess of CPP molecules and high siRNA concentrations (above the therapeutic range) and/or association with reagents that disrupt endosomes are generally necessary (Akita et al., 2010; Cantini et al., 2013; El-Sayed et al., 2009; Endoh and Ohtsuki, 2009; Erazo-Oliveras et al., 2012; Lee et al., 2008; Margus et al., 2012; van Asbeck et al., 2013; Zhang et al., 2014) . Imaging studies reveal the vast majority of CPPsiRNA complexes trapped for extended periods in intracellular vesicles with little or no cytoplasmic localization (Al-Taei et al., 2006; El-Sayed et al., 2009; Erazo-Oliveras et al., 2012; Fretz et al., 2007; Fuchs and Raines, 2004; Maiolo et al., 2005; Verdurmen et al., 2011) . R-CPPs have thus been used more as coformulants for enhancing transfection efficiencies, rather than as primary components of synthetic siRNA delivery systems (Beloor et al., 2012; Cheng and Saltzman, 2011; Kim et al., 2010; Margus et al., 2012; Nakamura et al., 2007) .
We previously used the homopolymeric R-CPP nona-D-arginine (9DR) for delivering electrostatically complexed siRNA by covalently coupling 9DR to peptide/protein ligands that bind cell-surface receptors Subramanya et al., 2010) . This ''ligand-9R'' approach not only targeted siRNA specifically to cells bearing a receptor for the ligand, but also induced potent gene silencing . This raised the question of how ligand attachment to 9R elicited functional siRNA delivery, which has been the formidable challenge to realizing the potential of siRNA therapeutics.
By correlating live-cell microscopy observations of siRNA localization with measurements of siRNA bioactivity, we determined that whereas native 9R peptides (D and L isoforms) lost their intrinsic ability to translocate upon siRNA complexation, ligand-9R enabled cytoplasmic siRNA delivery (1) at the cell surface by tethering microparticles on the plasma membrane in a receptor-dependent manner, which led to membrane inversion at the site of binding and rapid siRNA translocation; and (2) from late endosomes using mechanisms that required endosomal protease activity. The latter occurred only when the L isoform of 9R was used (ligand-9LR) and prolonged the dynamics of gene silencing. Our results demonstrate that attachment to ligands restores the fundamental property of CPP translocation, eliciting effective delivery of siRNA.
RESULTS

9R Peptides Effectively Translocate Covalently Attached Molecules but Not siRNA
In preliminary analyses of 9R translocation, the murine neuroblastoma cell line, Neuro2a, was exposed to Alexa 488 ($700 Da)-labeled 9DR or 9LR. Both peptides became cell associated within 1 hr and a significantly higher uptake occurred with 9DR by 24 hr ( Figure 1A ) in terms of cell numbers and levels per cell ( Figure 1B , left and right, respectively). 9D/LR peptides also translocated covalently conjugated recombinant GFP protein ( Figure 1C ) and 9DR-GFP again accumulated to higher levels at 24 hr ( Figure 1D ). Thus, covalent attachment of low molecular weight or macromolecular cargo to 9R did not hamper cellular uptake and 9DR displayed better translocation properties, concurring with previous reports documenting superior cellpenetrating activity of protease-resistant D-oligomers of arginine (Kamei et al., 2008; Tü nnemann et al., 2008; Verdurmen et al., 2011; Wender et al., 2000) .
We next evaluated siRNA delivery by the cationic 9R peptide. siRNA was effectively complexed by 9D/LR peptides forming nanoparticles at peptide molar excesses of 10 and above (Figures S1A and S1B available online). However, transfection efficiencies in Neuro2A cells were relatively poor and comparable with the commercial transfection reagent Lipofectamine 2000 only at peptide:siRNA molar ratios R20:1 (Figures 1E and 1F ). GFP siRNA complexed to 9DR or 9LR did not silence GFP expression in Neuro2a cells stably expressing the protein (Figures 1G and 1H) . Therefore, 9R peptides poorly translocated siRNA, unless used at a high molar excess (>50; Cantini et al., 2013; Wang et al., 2007; Zhang et al., 2014) .
9R Peptides Effectively Translocate siRNA when
Attached to a Cell-Binding Ligand RVG, a 32-amino acid peptide derived from the Rabies virus glycoprotein, binds nicotinic acetylcholine receptor (nAchR) subunits and directs tropism toward receptor-bearing cells Subramanya et al., 2010) . When chimeric with RVG, both 9R peptides bound siRNA and formed nanoparticles ( Figures S1C and S1D ). Fusing 9R to another targeting ligand, a single chain antibody, also did not significantly change siRNA binding (data discussed below, Figures S1E and S1F).
Attachment of 9R to RVG dramatically enhanced uptake of complexed siRNA in Neuro2a cells that express nAchR. Mean fluorescence intensities (MFIs) were at least 2 logs higher 24 hr following treatment (627 ± 124 and 1,527 ± 121 for RVG-9DR and RVG-9LR, respectively [Figures 2A and 2B] compared to 6.7 ± 0.2 and 11.2 ± 1.4 for 9D/LR peptides at a 10:1 peptide: siRNA ratio and 81 ± 0.66 with Lipofectamine 2000 [ Figures  1E and 1F] ). Importantly, RVG-9R:siRNA complexes effectively silenced gene expression ( Figures 2C, 2D , and S2) and here, siRNA complexed to RVG-9LR silenced GFP better than RVG-9DR and Lipofectamine 2000 (GFP-negative cells increased by 69.8 ± 2.7%, 42.1 ± 23. 4% and 46.6 ± 19%, respectively [Figure 2D] ). Thus, attachment of 9R to RVG likely enabled delivery of siRNA to cytoplasm, which is key for RNA interference (RNAi; Wei et al., 2011) .
Coupling 9D/LR to another targeting ligand-a murine single chain antibody scFvCD7 (Figures S1E and S1F) that binds the CD7 molecule expressed on human T cells -similarly enhanced siRNA uptake into the human T cell line Jurkat (MFIs of 70.83 ± 26.05 and 104.6 ± 12.27 with scFvCD7-9D/LR versus 18.60 ± 0.82 and 20.97 ± 0.99 for 9D/ LR and 3.81 ± 0.17 for Lipofectamine 2000; Figure 2E ) and appreciably silenced target CD4 mRNA levels as early as 4 hr after treatment (64.5 ± 5.9% and 65.6 ± 3.6% with siCD4 in comparison to siLuc complexed with scFvCD7-9D/LR; Figure 2F ). Native 9D/LR peptides as well as Lipofectamine 2000 failed to elicit target mRNA knockdown, in keeping with the highly resistant nature of Jurkat cells to transfection. Thus, the observations were not unique to RVG-9R but are a feature of the ligand-9R delivery platform. Attachment to a cell-binding ligand therefore transforms 9R, a poor siRNA delivery agent, into a highly effective siRNA carrier for gene silencing, even in cells resistant to conventional transfection methods.
RVG-9R Mediates Cytoplasmic Translocation of siRNA
The effective siRNA uptake and gene knockdown attained with RVG-9R, unlike with 9R peptides, suggests a trafficking pathway that ultimately resulted in cytoplasmic siRNA delivery. Two mechanisms are implicated in the cellular entry of CPPs and their attached cargo: energy-independent direct translocation at CPP concentrations of R10 mM (Nakamura et al., 2007; Rothbard et al., 2005; Rydströ m et al., 2011) and endocytosis mechanisms, such as macropinocytosis, at %5 mM (Duchardt et al., 2007; Fischer et al., 2004; Madani et al., 2011; Payne et al., 2007; Verdurmen et al., 2011; Wadia et al., 2004) . The final concentration of the RVG-9R peptides in siRNA translocation experiments ranged between 2 and 5 mM, which is at or below the threshold value that elicits direct translocation into the cytosol. The requirement of a ligand for cellular entry was indicative of receptor binding and therefore receptor-mediated endocytosis. Incubation at 4 C reduced, but did not abolish, cellular uptake of RVG-9R:siFITC complexes, indicating that temperature-independent mechanisms also play a role in ligand:9R uptake ( Figure S3A ).
Time-lapse imaging of Neuro2A cells exposed to RVG-9R: siFITC complexes revealed multiple small particle-like structures $1-3 mm in diameter accumulating and tethering on the plasma membrane ( Figure 3A ; see also Movies S1 and S2). Strong fluorescence (green) spread throughout the cytoplasm after influx of these particles, typically by about 20 min after treatment (26.4 ± 2.7 min and 22.1 ± 2.8 min with RVG-9DR/LR respectively, Figures 3A and 3B) . This translated to significant target mRNA knockdown within 1 hr after transfection, confirming early delivery of functional siRNA ( Figure 3C ). Some siRNA (red) colocalized with early EEA1+ endosomes (green, Figure 3D) ; however, late endosomes (labeled with the red LysoTracker dye) were completely devoid of siRNA (green, Figure 3A ) at these early times. Pretreatment with the actin depolymerizing agent cytochalasin D or the dynamin inhibitor dynasore did not significantly affect cytoplasmic siRNA fluorescence at 1 hr after exposure to peptide-siRNA complexes (green, Figure 3E ), although it reduced intracellular punctate fluorescence in cells exposed to transferrin (red, Figure S3B ). These data indicate that RVG-9R: siRNA delivery to the cytoplasm occurs rapidly in an actin/dynamin-independent manner across the plasma membrane or from very early endosomes.
RVG-9R:siRNA Complexes Induce Topical Membrane Inversion
Because 9D/LR:siRNA complexes did not associate with the plasma membrane for longer times ( Figure 3A extreme right, no microparticles seen by 22 min) or lead to vesicular or cytoplasmic fluorescence (see Movies S3 and S4), ligand-receptor binding appeared critical for initiating cellular entry of RVG-9R:siRNA complexes. Indeed, pretreatment of Neuro2A with a-bungarotoxin, a competitive inhibitor of RVG significantly reduced uptake of RVG-9LR:siFITC (Figure 4A) . We investigated if plasma membrane inversion, a mechanism identified in the energy-independent entry of 9R into cells (Hirose et al., 2012) , occurred at the site of ligand-9R/siRNA-receptor binding. Exposure of cells treated with RVG-9LR:siRNA complexes resulted in strong costaining with Alexa 568 -labeled annexin V within 30 min indicating membrane inversion (Figures 4B and 4C) . Strong annexin V positivity persisted for up to and beyond 2 hr in cells treated with RVG9D/LR:siRNA ( Figure 4C ); surprisingly however, this did not result in a loss of membrane integrity or cell cytotoxicity (measured by a lack of lactate dehydrogenase in culture medium and the Alamar blue cytotoxicity assay respectively, data not shown). Accordingly, most cells were no longer annexin V positive at 24 hr, but continued to remain positive for siFITC, signifying membrane inversion was temporary ( Figure 4C ). Annexin V signals were not detected on cells treated with RVG peptide lacking 9LR or 9LR:siRNA complexes, indicating that ligand attachment as well as the presence of the CPP was essential for membrane inversion in the context of complexed siRNA. Cells exposed to RVG-9LR alone were also positive for annexin V, albeit to a lesser extent, indicating that polyplex formation in the presence of siRNA increased exposure of the inner membrane.
We next resorted to generating siRNA complexes in situ by adding RVG-9R to Neuro2A cells in medium containing siRNA rather than using preformed siRNA complexes, because the kinetics of membrane inversion with the latter were too rapid to be captured in movie format. This strategy enabled visualization of peptide:siRNA complexes assembling at a reduced rate ($1-2 hr) and also significantly reduced subsequent cytoplasmic fluorescence. For these experiments, we restricted our investigations to RVG-9LR because the two peptides appeared to display comparable dynamics of cellular entry and similarly induced annexin, at least at early time points. Annexin V staining (red) was highly localized to the site of RVG-9LR:si-FITC binding (green), and appeared to occur even from vesicle-like structures within the cell (Figure 4D , arrows; see also Movie S5). No annexin V-staining was detected in the presence of a-bungarotoxin, indicating that ligand-receptor binding and not direct CPP interactions with the cell membrane initiates the mechanism even with siRNA complexes formed in situ (data not shown). These observations provide evidence that ligand-9R induces transient membrane inversion, at the regions corresponding to the ligand-9R binding sites, and that receptor binding by ligand-9R increases CPP concentration in a localized manner to above the threshold required for eliciting membrane flipping. See also Figure S3 and Movies S1, S2, S3, and S4. The L-Isoform of 9R Enables Cytoplasmic siRNA Delivery by RVG-9R from Endosomes Energy-requiring mechanisms such as receptor-mediated endocytosis also possibly contribute to cellular uptake (Figure S3A) . We investigated if ligand binding induced receptor aggregation. It is not known which of the nAchR subunits the RVG peptide binds. We therefore expressed the a6-subunit fused with mCherry, which in recombinant form is known to localize, traffic, and associate with a4 and b2 subunits of the nAchR expressed in Neuro2A cells (Drenan et al., 2008) . Clearly, membrane assembly of ligand-9R:siRNA complexes, generated by adding RVG-9LR into medium containing siFITC, aggregated membrane receptors evidenced by labeled nAchR receptor subunits (red) coalescing with RVG-9LR:siRNA complexes (green) ( Figure S4A ; see also Movie S6).
Live cell microscopy at later time points after transfection revealed siRNA (green) in the cytoplasm as well as in LysoTracker-positive (red) endocytic vesicles, indicating that RVG-9R-siRNA complexes also get endocytosed and traffic within vesicles that mature into late endosomes ( Figure 5A ). Figure S4 and Movie S6.
Even nuclear fluorescence was evident in keeping with previous reports of cytoplasm to nuclear transport of 9R (Zaro et al., 2009 ). 9D/LR:siRNA complexes were also endocytosed but completely resident within vesicles at these times ( Figure S4B ) accounting for the uptake but insignificant target mRNA knockdown observed in Figure 1 . At 24 hr, RVG-9DR:siRNA-treated cells had a markedly punctate fluorescence distribution with increased ''arrest'' of green siRNA within late endosomal compartments with little/no cytoplasmic staining ( Figure 5A ). On the other hand, prominent cytoplasmic fluorescence was still evident in RVG-9LR:siRNA-transfected cells. Image analysis revealed cytoplasmic siRNA in approximately 40% of RVG-9LR-transfected cells in contrast to <10% of RVG-9DR-treated cells at 24 hr ( Figure S4C ).
These data suggested that siRNA release continues to occur after endosome maturation from intracellular vesicles with RVG-9LR:siRNA. To explore this, we expressed GFP-reportertagged wild-type and dominant-mutant Rab GTPases, Rab5 S34N and Rab7 T22N, which block early and late endosome maturation (Barbieri et al., 2000; Feng et al., 1995) . Expression of the mutant GFP-Rab proteins did not alter the dominantly endosomal localization of siRNA (red) at 24 hr in Neuro2a cells treated with RVG-9DR:siCy5 ( Figures 5B and S4D ). On the other hand, in RVG-9LR:siCy5-exposed cells, inhibition of endosomal maturation resulted in an almost complete accumulation of red fluorescence within vesicles and a marked reduction in cytoplasmic fluorescence when compared with cells expressing wild-type Rab5 or Rab7. Thus, whereas cytoplasmic siRNA delivery by RVG-9DR is restricted to a limited time early after transfection by the membrane-flipping mechanisms, RVG-9D/ LR:siRNA extends siRNA release from endosomes, and vesicle maturation actively contributes to this.
We carried out a temporal analysis of gene knockdown in Neuro2a cells to determine if the clear-cut differences in cytoplasmic siRNA fluorescence with the two RVG-9R peptides at later time points after transfection were reflected in siRNA bioactivity. RVG-9R:siSOD1 effectively reduced target mRNA levels (SOD-1) for up to 24 hr, and a marginally higher knockdown was elicited with RVG-9LR:siRNA ( Figure 5C ). Whereas cells treated with RVG-9DR:siSOD1 began to re-accumulate SOD-1 mRNA at 36 hr, significant knockdown persisted in RVG-9LR: siSOD1-treated cells in accordance with the persisting cytoplasmic siRNA fluorescence at 24 hr ( Figure 5B ). siRNA effects ceased by approximately 96 hr, given the rapid doubling time of Neuro2A cells ($0.8 day), which governs intracellular siRNA concentration and thus duration of gene silencing (Bartlett and Davis, 2006) . A similarly prolonged silencing activity to beyond 36 hr was also noted with scFvCD7-9LR-delivered siCD4 in Jurkat cells, whereas mRNA knockdown with scFvCD7-9DR: siCD4 was short-lived ( Figure 5D ). Thus, although early siRNA translocation depends on both ligand and CPP functions, the CPP, through its stereochemistry, critically influences siRNA release from late endosomes.
siRNA Release from Endosomes Depends on Proteolytic Activity The above observations imply that sensitivity of 9LR, but not 9DR, to late endosomal proteases may contribute to siRNA release into the cytoplasm. siRNA complexed with the two RVG-9R peptides was stable at 37 C for up to 3 hr of exposure to RNase A in serum-free medium, whereas naked siRNA was degraded rapidly within 30 min, demonstrating shielding of complexed siRNA from nucleases ( Figure 6A ). However, recovery of intact siRNA from RVG-9LR:siRNA complexes incubated in human serum containing medium was significantly reduced by 3 hr, whereas siRNA associated with RVG-9DR was intact for as long as 24 hr ( Figure 6B ). This suggested that serum protease-mediated degradation of 9LR in RVG-9LR may have exposed siRNA to serum nucleases while the protease-resistant 9DR isoform continued to protect complexed siRNA. We explored whether a similar scenario existed in the late endosome. We treated Neuro2a cells with the membrane-permeable inhibitor E-64d that blocks endosomal cysteine peptidase activity. This dramatically accumulated fluorescence in vesicles and reduced cytoplasmic siRNA localization in RVG-9LR:siRNAtreated cells in comparison to untreated cells at 24 hr after transfection ( Figures 6C and 6D) . Furthermore, E-64d treatment also selectively and significantly affected mRNA knockdown by RVG-9LR:siRNA indicating that some level of degradation of the 9R carrier in the late endosome may be a dominant factor contributing to the overall efficiencies of RNAi achieved by ligand-9LR delivery systems ( Figure 6E ).
Collectively, these data demonstrate that cell-binding ligands can transform 9R peptides into effective siRNA delivery agents by eliciting trafficking mechanisms that result in cytoplasmic delivery of siRNA (Figure 7) .
DISCUSSION
Cationic CPPs, such as 9R, form nano-sized particles with negatively charged siRNA. However, when used in this manner for ''actively'' transporting siRNA into cells, gene knockdown is not very effective because siRNA is poorly transferred to the cytoplasm (Endoh and Ohtsuki, 2009; Margus et al., 2012) . We investigated mechanisms whereby attachment to cell-binding ligands restores CPP function, transforming 9R peptides into potent agents for siRNA delivery.
Ligand attachment to 9R increased siRNA uptake by more than two orders of magnitude. Ligand-receptor binding was vital for uptake; however, mechanistic translocation of siRNA critically depended on 9R. Live confocal microscopy revealed fluorescent ligand-9R:siRNA complexes tethering as microparticles on the plasma membrane whose influx resulted in rapid cytoplasmic distribution of siRNA fluorescence and mRNA knockdown within 1 hr. The process had little dependence on actin/dynamin function. Annexin V staining revealed topical inversion of the cell membrane focused at the site of ligand-9R:siRNA binding. These observations are strikingly consistent with a study that found dodeca-arginine (R12) induced microparticle formation on cell membranes and subsequent inversion of the lipid bilayer at these spots influxed R12 directly into the cell cytoplasm (Hirose et al., 2012) . The process was energy/ temperature-independent and not affected by cytochalasin D or dynasore. The requirement of the ligand for 9R-induced membrane inversion when 9R is associated with siRNA suggests that tethering of the CPP in proximity to the cell surface through receptor binding, which in turn increases CPP concentration locally, is required for eliciting membrane inversion.
Alternatively, conjugation of hydrophobic moieties to R12 increased affinity for the plasma membrane, favoring the formation of multimeric particles at the cell surface (Hirose et al., 2012) . Thus, ligand attachment, in addition to mediating cell binding, could be promoting amphiphilicity of 9R to induce translocation through similar mechanisms.
Ligand-9R:siRNA complexes also trafficked through Rab5+ and Rab7+ endosomes. Octa-arginine (R8), at <5 mM concentrations, enters cells by macropinocytosis (Appelbaum et al., 2012) after binding to membrane proteoglycans and phospholipids (Erazo-Oliveras et al., 2012; Verdurmen et al., 2011) . However, the evidence of ligand-induced receptor aggregation suggests that the endocytic trafficking pathway elicited is a consequence of receptor-mediated endocytosis. The nuclear siRNA fluorescence is also in agreement with observations that strongly endocytosed CPPs, which can result from attachment to endocytosed ligands, result in nuclear transport (Zaro et al., 2009 ). The endocytic route also contributed to cytosolic delivery of siRNA at later times, but only when ligand-9LR was used for delivery. It is possible that fluorophore released by nucleasedegraded siRNA that has dissociated from ligand-9LR due to protease action could have contributed to cytosolic fluorescence. However, prolonged mRNA knockdown indicated functional siRNA activity in the cytosol and this was not the case with ligand-9DR:siRNA despite its accumulation within LysoTracker-positive late endosomes. Therefore, endosomal sequestration, the major limiting factor for CPP-mediated siRNA delivery, was appreciably overcome using ligand-9LR.
Our investigations into siRNA binding by RVG-9R peptides reveal strong association and tight complex formation between the two at low pH ( Figure S4E ). In addition, the ligand-CPP:siRNA complex is no longer tethered to the membrane and dissociated from the receptor at low pH within late endosomal compartments. This likely hinders membrane flipping or other mechanisms such as ''pore formation,'' which require multidentate hydrogen bonds between the guanidinium side group in 9R and the negatively charged phospholipids enriched in the intraluminal lipid bilayers of late endosomes. (Kobayashi et al., 2001; Matsuo et al., 2004; Mishra et al., 2011; Yang et al., 2010; Ziegler, 2008) . Disruption/destabilization of ligand-9LR:siRNA by late endosomal proteases could be requisite to promote CPP-membrane interactions for continued release of siRNA. In keeping with our data, substitution of R-CPPs and oligo-L-arginines with D-amino acids, at the terminal positions, obstructed degradation by endosomal proteases, reducing cytoplasmic localization of CPP, bioactivity of attached cargo, and transfection efficiencies (Abes et al., 2008; Fischer et al., 2010; Mason et al., 2007; Verdurmen et al., 2011; Wu et al., 2007) . The association of RISC machinery components with intraluminal vesicles and membranes of the late endosome (Lee et al., 2009; Saleh et al., 2006; Siomi and Siomi, 2009 ) also raises the possibility that ligand-9LR instability, in combination with ionic competition for nucleic acid binding at lower pH, may displace siRNA for direct loading onto the endosomal RISC, enhancing the dynamics of RNA silencing in the cytoplasm.
Hydrophobic components, such as stearyl and cholesteryl groups, lipid membranes, and other agents that promote endosomal escape, have conventionally been used to improve cytosolic delivery of R-CPPs and their cargo (El-Sayed et al., 2009; Endoh and Ohtsuki, 2009; Hayashi et al., 2011; Kim et al., 2006 Kim et al., , 2010 Nakamura et al., 2007; Nakase et al., 2004; Tö nges et al., 2006) . Our data demonstrate that attachment of 9R and possibly other CPPs to cell-binding ligands can overcome the key rate-limiting step of delivery to the cytosol as depicted schematically in Figure 7 . We hypothesize that ligand-receptor binding induces localized accumulation of microparticle-like structures on the plasma membrane, concentrating CPPs to a threshold level that induces siRNA translocation into the cytosol across the membrane from the exterior and/or from endosomes. The mechanism involved is CPPmediated membrane flipping, which is actin/dynamin independent when it occurs at the plasma membrane. This constitutes the major route of cytosolic delivery. Late endosome to cytosol is a second, more controlled route that extends the kinetics of gene silencing through proteolytic disruption of ligand-9LR:siRNA complexes, promoting membrane-CPP interactions. 9D/LR:siRNA complexes are not capable of effectively engaging either route for cellular entry unless used at very high concentrations.
Because the ligand-9R strategy relies on surface receptor expression, it can be effectively used for primary and suspension cells independent of confluence under conditions identical to those established in cell lines. Through the use of a ligand that confers cell specificity, the approach has the benefit of concentrating siRNA activity within select cells, enabling reduced dosing, which is key for in vivo treatment potency. Alternatively, ligands that bind receptors on multiple cell types, e.g., epidermal growth factor transferrin and those of the integrin family, can expand applicability to whole cell populations (Ming, 2011). The path taken by ligand-9R from the cell exterior to the cytosol begins with binding of the ligand to its cell-surface receptor. Cellular entry then proceeds by localized membrane inversion at the site of ligand-9R microparticle binding and accumulation on the plasma membrane and/or within early endosomes. siRNA then quickly translocates across the membrane and diffuses in the cytoplasm. This pathway is the major route of cytosolic delivery for both ligand-9D/LR:siRNA complexes. siRNA translocation from late endosomes after endocytosis is a second, slower, and controlled route that results only when siRNA is complexed to ligand-9LR. Blocking vesicle maturation or inhibiting endosomal proteases interferes with the process, indicating that some level of proteolytic degradation of the ligand-9LR carrier is required. Late endosome to cytosol translocation could occur by ''membrane-flipping'' or other such mechanisms. 9D/LR complexes are not capable of effectively engaging either route for cellular entry unless used at very high concentrations.
This flexibility makes the ligand-9R a compelling approach for harnessing the therapeutic potential of siRNA.
SIGNIFICANCE
Cationic cell-penetrating peptides (CPPs), such as nonaarginine (9R), that translocate covalently attached biomolecules into the cellular cytoplasm poorly deliver electrostatically complexed siRNA. Our study highlights the proficiency of 9R in functional siRNA delivery when chimeric with peptide and protein ligands (ligand-9R) that bind cellular receptors. By correlating siRNA bioactivity with live-cell confocal and time-lapse microscopy observations, we conclude that ligand-9R primarily enables rapid siRNA translocation into the cytosol through microparticles that accumulate on cell membranes upon ligand attachment to the receptor inducing localized topical membrane inversion. siRNA is also released into the cytosol from late endosomes after receptor-mediated endocytosis of ligand-9R complexes, but only with the L isoform of 9R (ligand-9LR), and is critically dependent on endosomal protease activity. siRNA complexed to ligand-9LR efficiently prolongs target gene mRNA knockdown even in cells resilient to transfection, such as human T cells. siRNAs are an indispensable analytical platform for biological target validation in vitro. siRNAs have, however, been underexploited as a therapeutic platform because effective siRNA delivery systems are lacking. Our studies highlight that 9R and possibly other CPPs can be harnessed for effective siRNA transport by routing them to receptors using cell-binding ligands because this initiates a pathway that synergizes cellular uptake with mechanisms that lead to cytosolic release-a critical requirement for the functional outcome of siRNA.
EXPERIMENTAL PROCEDURES
siRNA Transfection Experiments 9D/LR or RVG-9D/LR was incubated with siRNA (100 pmol) in serum-free Dulbecco's modified Eagle's medium (DMEM) at molar ratios ranging between 5 and 25 for 20 min at room temperature and added to Neuro2a cells cultured in DMEM-10 at final concentrations between 1 and 5 mM. Experiments with scFvCD7-9D/LR used 5 mM protein on human Jurkat T cells. Carrier-to-siRNA ratio was maintained at 10:1 unless otherwise mentioned. Lipofectamine 2000 (Invitrogen) was used according to manufacturer's instructions. For inhibiting actin/dynamin activity, Neuro2a cells were pretreated for 1 hr with 5 mM cytochalasin D (Sigma) or 80 mM dynasore (Sigma). For inhibiting endosomal proteases, Neuro2a cells were pretreated for 1 hr with 40 mM E-64d (Sigma) and chased in medium containing E-64d after addition of peptide:siRNA complexes. For blocking nAchR, Neuro2a cells were pretreated for 30 min on ice with 10 À5 M A 568 -labeled a-bungarotoxin prior to addition of peptide:siRNA complexes. Mammalian expression plasmids encoding (1) wild-type Rab5, Rab7, Rab5(S34N), and Rab7(T22N) fused in frame to eGFP; and (2) a4, b2, and a6 (the latter fused to mCherry) subunits of the mammalian nAchR were transfected into Neuro2a cells using Lipofectamine 2000 48 hr prior to treatment with RVG-9R:siRNA complexes. Gene silencing was analyzed by flow cytometry for reporter GFP expression or qPCR for murine SOD1 and human CD4 mRNA levels normalizing to murine GAPDH and human beta-actin, respectively.
Confocal Microscopy
Neuro2a cells seeded and cultured in complete medium on poly-L-lysine (Sigma-Aldrich) treated coverslips were incubated with 9D/LR-GFP (1 mM) or peptide:siRNA complexes (300 pmol siRNA, final concentration 3 mM, 10:1 molar ratio). Confocal microscopy was performed in most cases, without washing or fixing, using Volocity spinning disc Nikon TE2000 confocal microscope equipped with an environmental chamber (LIVE CELL; Pathology Devices) and a Nikon Perfect Focus with a 603 Nikon objective (ND 1.4) or a Leica TCS SP5 Spectral Confocal Microscope at 633 magnification. Hoechst 33342 was used to distinguish nuclei; LysoTracker Red to stain late endosomal vesicles. For experiments depicting membrane interactions of ligand-9R: siRNA complexes, siFITC (300 pmol, final concentration 3 mM) and/or Alexa 568 -labeled annexin V was first added to Neuro2A cells followed by addition of RVG-9LR (10:1 peptide:siRNA ratio). Early endosomes were detected in cells fixed with 4% paraformaldehyde by staining with rabbit anti-EEA1 and mouse anti-rabbit FITC (green) antibodies. All images were processed using Volocity 6.2.1 software (Improvision/PerkinElmer). Quantification of image intensities was performed with Image J 1.49b software.
Ribonuclease A and Serum Protection Assays Peptide:siRNA complexes (100 pmol siRNA, 10:1 ratio) were incubated at 37 C in 100 ng RNase A or 50% human AB serum (not heat inactivated) contained in DMEM. Timed aliquots were treated with proteinase K (50 mg/ml, 10 min at 25 C) and RNA extracted with phenol chloroform-isoamyl alcohol (25:24:1 v/v). All samples were subjected to electrophoresis on a 2% agarose gel with ethidium bromide. Band intensities were estimated using the Image J software.
Statistical Analysis
Results are presented as mean ± SD or mean ± SEM as indicated. Statistical significance was calculated using data from three independent experiments using one-way ANOVA with Bonferroni's multiple-comparison test for pairwise comparisons within groups. Otherwise, comparisons were made using a twotailed t test. 
SUPPLEMENTAL INFORMATION
